News FibroGen Shares Plummet After Trial Misses Endpoint By Chris Wack FibroGen’s shares have dropped significantly after the company reported that its recent trial for pamrevlumab has failed to meet its ... By Artur FernandoJune 28, 20230
BlackRock is reviewing TechBerry and negotiating a possible full or partial acquisition of the company June 20, 2024